Alqumber Nedhal A, Choi Jong-Woo, Kang Min-Kyu
Department of Plastic and Reconstructive Surgery, University of Ulsan College of Medicine, Seoul Asan Medical Center, Seoul, Republic of Korea.
Ann Plast Surg. 2019 Jul;83(1):55-62. doi: 10.1097/SAP.0000000000001865.
Angiosarcomas are extremely aggressive malignant tumors that arise from vascular endothelial cells. The risk factors, etiology, prognostic factors, and optimal management strategies for angiosarcomas are as yet unknown.
We retrospectively analyzed data from 15 patients who were treated in Asan Medical Center, Seoul, Republic of Korea, in the past 12 years, to assess the effect of different treatment modalities and reconstructive methods on the locoregional recurrence, metastasis, and overall survival.
A total of 15 patients were identified (median age at diagnosis, 72 years; range, 61-82 years). Median tumor size was 6 cm. Median follow-up was 287 days. The median overall survival was 14.96 months; a total of 13 (87%) patients had died by the end of the study.The median locoregional recurrence, metastasis, and overall survival were 7.3, 6.5, and 16.7 months, respectively. On univariate analysis, the use of adjuvant therapy after surgery (vs surgery without adjuvant therapy) was associated with delayed median time to detection of recurrence (7.9 months vs 3.1 months, respectively; P = 0.825), delayed median time to metastasis (8.7 months vs 3.1 months, respectively; P = 0.191), and better median overall survival (7.3 months vs 3.1 months, respectively; P = 0.078).The use of flap versus skin graft as a reconstructive method was associated with delayed median recurrence (8.75 vs 7.32 months, respectively; P = 0.274) and earlier median metastasis (3.75 vs 6.53 months, respectively; P = 0.365), but the same median overall survival of 16.7 months (P value: 0.945) and tumor smaller or bigger than 5 cm show earlier median time to detection of recurrence (4.17-7.32 months; P = 0.41), earlier median time to metastasis (3.75-6.53 months; P = 0.651), but better median overall survival of 18.21 versus 16.7 months, respectively (P = 0.111).
Multimodal treatment that combines surgery with adjuvant therapy is the best management strategy that influences survival positively in patients with angiosarcoma. The study shows that the reconstructive method does not affect the prognosis in these patients. So it is better to choose the simplest suitable resection and reconstructive method with the least complications and to avoid unnecessary procedures.
血管肉瘤是起源于血管内皮细胞的极具侵袭性的恶性肿瘤。血管肉瘤的危险因素、病因、预后因素及最佳治疗策略尚不清楚。
我们回顾性分析了过去12年在韩国首尔峨山医学中心接受治疗的15例患者的数据,以评估不同治疗方式和重建方法对局部区域复发、转移及总生存的影响。
共纳入15例患者(诊断时的中位年龄为72岁;范围为61 - 82岁)。肿瘤中位大小为6 cm。中位随访时间为287天。中位总生存期为14.96个月;到研究结束时共有13例(87%)患者死亡。局部区域复发、转移及总生存的中位时间分别为7.3个月、6.5个月和16.7个月。单因素分析显示,术后使用辅助治疗(与未使用辅助治疗的手术相比)与复发检测中位时间延迟有关(分别为7.9个月和3.1个月;P = 0.825),转移中位时间延迟(分别为8.7个月和3.1个月;P = 0.191),以及更好的总生存中位时间(分别为7.3个月和3.1个月;P = 0.078)。使用皮瓣与植皮作为重建方法与复发中位时间延迟有关(分别为8.75个月和7.32个月;P = 0.274)和更早的转移中位时间(分别为3.75个月和6.53个月;P = 0.365),但总生存中位时间相同,均为16.7个月(P值:0.945),且肿瘤大小大于或小于5 cm显示复发检测中位时间更早(4.17 - 7.32个月;P = 0.41),转移中位时间更早(3.75 - 6.53个月;P = 0.651),但总生存中位时间分别为18.21个月和16.7个月,前者更好(P = 0.111)。
手术联合辅助治疗的多模式治疗是对血管肉瘤患者生存有积极影响的最佳治疗策略。该研究表明重建方法不影响这些患者的预后。因此,最好选择并发症最少的最简单合适的切除和重建方法,避免不必要的操作。